Interstitial cells of Cajal in diabetic gastropathy

糖尿病胃病中的卡哈尔间质细胞

• 批准号: 7806504
• 负责人: Tamas Ordog
• 金额: $ 24.52万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-01 至 2011-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7806504
• 关键词: Address; Adolescent; Adult; Affect; Animals; Attention; Blood Glucose; C-KIT Gene; CD34 gene; Cells; Characteristics; Chick Embryo; Clinical; Clonality; Commit; Creation of jejunostomy; Data; Development; Diabetes Mellitus; Diet; Disease; Dyspepsia; Electric Stimulation; Enteral; Fundus; Gastroparesis; Generations; Genes; Goals; Growth Factor; Growth Factor Receptors; Harvest; Home environment; In Vitro; Inbred NOD Mice; Insulin; Insulin-Like Growth Factor I; Interstitial Cell of Cajal; Intramuscular; Lead; Maintenance; Malnutrition; Mediating; Mediator of activation protein; Medical; Motor; Mus; Muscle; Myopathy; NOD/LtJ Mouse; Natural regeneration; Nausea and Vomiting; Neuropathy; Non obese; Non-Insulin-Dependent Diabetes Mellitus; Obstruction; Pacemakers; Pain; Parenteral Feedings; Pathogenesis; Patients; Pharmaceutical Preparations; Prevention; Proto-Oncogene Protein c-kit; Public Health; Quality of life; Refractory; Regulation; Relaxation; Residual state; Signal Transduction; Simian virus 40; Smooth Muscle; Somatomedins; Stem Cell Factor; Stem cells; Stomach; Stromal Neoplasm; Symptoms; Temperature; Therapeutic; Tissues; Transgenic Mice; Transplantation; Tumor Antigens; Work; adult stem cell; blood glucose regulation; cell type; diabetic; functional restoration; gastrointestinal; glycemic control; in vitro Model; in vivo; molecular marker; mouse model; neuromuscular; neurotransmission; non-diabetic; novel; prevent; research study; self-renewal; type I and type II diabetes

DESCRIPTION (provided by applicant): Thirty to 60% of patients with diabetes mellitus suffer from symptoms of gastropathy and gastroparesis, e.g. dyspepsia, pain, recurring nausea and vomiting and consequent malnutrition, impaired glycemic control, and diminished quality of life. Pathogenetic factors include systemic and myenteric neuropathy, which may lead to pylorospasm and reduced receptive relaxation of the fundus; smooth myopathy, which reduces contractility; and depletion of interstitial cells of Cajal (ICC), which leads to electrical dysrhythmias and reduced phasic contractions and contributes to impaired neuromuscular neurotransmission. ICC are also reduced in idiopathic gastroparesis. Current therapeutic approaches, which are frequently inadequate, include diet, jejunostomy or parenteral feeding, attention to blood glucose control, gastric decompression, reducing pyloric tone, and stimulation of residual gastric motor function with gastrokinetic drugs or electrical pacing. Importantly, recent data indicate that patients with reduced ICC tend to be refractory to medical therapy and respond poorly to electrical stimulation. Thus, patients suffering from gastroparesis would likely benefit from prevention of ICC depletion or replacement of the missing cells. In this project we will explore, in animal and in vitro models, the following approaches to prevent and restore ICC: We plan to examine whether treatments with insulin and other growth factors, which are reduced or ineffective in diabetes but are required for the long-term maintenance if ICC, could prevent or restore the loss of these cells in nonobese diabetic mice. Our second aim is to develop conditionally immortalized ICC and examine whether these cells can restore rhythmic electrical and contractile activity in organotypic cultures. Finally, we plan to isolate and characterize committed or multipotent precursors of ICC ("adult" stem cells), examine their developmental potential in vitro and in-vivo, and study their regulation and fate in mice with diabetic and nondiabetic gastroparesis. The proposed experiments could lead to novel treatment options to restore function that is lost in patients with diabetic or nondiabetic gastroparesis. Relevance to public health: Gastroparesis causes diminished quality of life in a significant proportion of patients with diabetes. Current therapy aims at stimulating residual function and is frequently inadequate. The goal of this project is to develop novel treatments that focus on restoring, or preventing the loss of, cells that are reduced in this disorder.

描述（由申请方提供）：30%至60%的糖尿病患者患有胃病和胃轻瘫的症状，例如消化不良、疼痛、复发性恶心和呕吐以及随之而来的营养不良、血糖控制受损和生活质量下降。致病因素包括全身性和肌间神经病变，其可能导致幽门痉挛和胃底的接受性松弛降低;平滑肌病，其降低收缩性;以及Cajal间质细胞（ICC）耗竭，其导致电节律障碍和阶段性收缩减少，并导致神经肌肉神经传递受损。ICC在特发性胃轻瘫中也减少。目前的治疗方法，这往往是不够的，包括饮食，空肠造口术或胃肠外喂养，注意血糖控制，胃减压，降低幽门张力，并与胃动力药物或电起搏刺激残余胃运动功能。重要的是，最近的数据表明，ICC减少的患者往往对药物治疗难治，对电刺激反应不良。因此，患有胃轻瘫的患者可能受益于ICC耗竭的预防或缺失细胞的替代。在这个项目中，我们将在动物和体外模型中探索以下预防和恢复ICC的方法：我们计划研究胰岛素和其他生长因子的治疗是否可以预防或恢复非肥胖糖尿病小鼠中这些细胞的损失，这些生长因子在糖尿病中减少或无效，但如果ICC需要长期维持。我们的第二个目标是开发条件永生化的ICC，并检查这些细胞是否可以恢复有节奏的电和收缩活动的器官型文化。最后，我们计划分离和鉴定ICC（“成体”干细胞）的定向或多能前体细胞，在体外和体内研究其发育潜力，并研究其在糖尿病和非糖尿病胃轻瘫小鼠中的调节和命运。拟议的实验可能会导致新的治疗选择，以恢复糖尿病或非糖尿病胃轻瘫患者失去的功能。与公共卫生的相关性：胃轻瘫导致相当一部分糖尿病患者生活质量下降。目前的治疗旨在刺激残余功能，但往往是不够的。该项目的目标是开发新的治疗方法，重点是恢复或防止在这种疾病中减少的细胞的损失。